Press release
U.S. Antiviral Drugs Market to Reach USD 23.61 Billion by 2030 Amid Falling COVID-19 Demand and Rising Generic Adoption
Antiviral Drugs Market
The rise of generic antiviral drugs and increased focus on affordable healthcare are reshaping market dynamics. While patented antiviral treatments still dominate, a wave of generic launches, expiration of key patents, and expanded access to telehealth and online pharmacies are catalyzing structural transformation. The growing prevalence of HIV-which accounted for nearly 37.7% of U.S. antiviral drug revenue in 2024-remains a critical driver for innovation in combination therapies and single-tablet regimens.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ U.S. antiviral drugs market valued at USD 26.41 billion in 2024, expected to reach USD 23.61 billion by 2030.
➤ HIV segment dominates with 37.7% share, supported by advanced antiretroviral therapy (ART) regimens.
➤ Branded antivirals hold 61.7% market share in 2024, led by FDA-approved fixed-dose combinations.
➤ Generic antivirals expected to grow at 1.7% CAGR as patents expire and affordability improves.
➤ DNA polymerase inhibitors projected to exhibit fastest growth in hepatitis and herpes treatment.
➤ Hospital pharmacies remain dominant distribution channels; online pharmacies gaining traction with telehealth adoption.
Market Segmentation
By type, branded drugs accounted for 61.7% of 2024 revenue due to their established clinical efficacy and large-scale use in chronic viral therapy. The generic segment, however, is projected to record steady positive growth through 2030, driven by lower costs and increased competition following the expiration of patents for major drugs like efavirenz and tenofovir. Companies like Teva, Mylan, and Sandoz are expanding affordable treatment options accessible through hospital and online channels.
By drug class, reverse transcriptase inhibitors (RTIs) hold the largest market share, forming the backbone of ART regimens for HIV management. DNA polymerase inhibitors are gaining share with their efficacy against hepatitis B and herpes simplex virus (HSV) infections. Continuous FDA approvals-including expanded use of Mavyret for pediatric hepatitis C in June 2025-underscore growing clinical innovation in the space.
By application, HIV continues to dominate due to ongoing treatment needs and government-backed ART programs. Meanwhile, herpes treatment is growing the fastest as diagnosis awareness improves and resistant virus strains drive R&D efforts. Combination therapies with better viral suppression and fewer side effects are helping expand patient adherence and quality of life.
Regional Insights
The U.S. antiviral landscape shows significant adoption variations across regions. East Coast states such as New York and Massachusetts maintain strong ART and hepatitis treatment programs. The Southern states, which face higher rates of chronic infections, exhibit growing demand for generics and public health-driven treatment expansion. The West Coast, particularly California, continues to lead clinical trials and antiviral research collaborations through academic and biotech partnerships.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Market Dynamics
Market Drivers
High prevalence of chronic infections like HIV and hepatitis B/C sustains long-term antiviral demand. FDA approvals of pediatric and combination regimens improve treatment accessibility. The expansion of telehealth and online pharmacies further enhances drug availability and prescription management.
Market Restraints
Reduced incidence of COVID-19 and influenza has curtailed short-term antiviral use. Moreover, high prices of branded drugs-such as the USD 84,000 cost for a 12-week Sovaldi course-limit affordability. Patient trust, insurance complexities, and reimbursement gaps remain significant barriers.
Market Opportunities
Patent expirations and FDA policies promoting generics create significant affordability opportunities. Ongoing research into drug-resistant strains, pediatric formulations, and combination therapies will stimulate sustainable innovation. The integration of antiviral treatments with digital health tools presents new patient engagement avenues.
Purchase This Exclusive Report at Just USD 4964 Only: https://www.datamintelligence.com/buy-now-page?report=antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ In-depth forecast of the U.S. antiviral drugs market through 2030.
✔ Analysis of key therapeutic areas including HIV, hepatitis, and herpes.
✔ Insights into emerging generic trends reducing healthcare cost burden.
✔ Evaluation of FDA regulatory developments influencing drug lifecycle.
✔ Competitive intelligence featuring top pharmaceutical players across antiviral categories.
Frequently Asked Questions (FAQs)
◆ What is the projected size and growth rate of the U.S. antiviral drugs market by 2030?
◆ Which antiviral drug class currently dominates the U.S. market?
◆ Who are the key players in the U.S. antiviral drugs industry?
◆ How are generics impacting the pricing and availability of antiviral treatments?
◆ What are the main challenges and growth opportunities for antiviral therapy developers?
Company Insights
F. Hoffmann-La Roche Ltd.
GSK plc.
AbbVie, Inc.
Merck & Co. Inc.
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Cipla Inc.
Aurobindo Pharma
Dr. Reddy's Laboratories Ltd.
ADARx Pharmaceuticals Inc.
Recent Developments:
June 2025: FDA approved expanded use of Mavyret for acute hepatitis C in children aged 3 and above.
February 2023: Ascend Elements partnered with Honda Motor Co. Ltd. for sustainable lithium recovery from antiviral drug manufacturing supply chains.
Conclusion
The U.S. antiviral drugs market is undergoing transformation amidst declining COVID-specific demand and rising accessibility of generics. Despite a moderate contraction in market value, long-term opportunities remain strong through HIV, hepatitis, and herpes therapies supported by FDA-backed innovation and competitive pricing structures. The transition toward affordable generics, pediatric indications, and online distribution is expected to reshape access, affordability, and compliance. With continuous research and robust industry engagement, the U.S. antiviral drug sector is poised to evolve toward equitable and sustainable healthcare outcomes through 2030.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release U.S. Antiviral Drugs Market to Reach USD 23.61 Billion by 2030 Amid Falling COVID-19 Demand and Rising Generic Adoption here
News-ID: 4221218 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
U.S. LiDAR Market to Reach USD 2.36 Billion by 2030, Fueled by Autonomous Vehicl …
The U.S. LiDAR market, valued at USD 679.4 million in 2024, is projected by DataM Intelligence to grow to USD 2,358.2 million by 2030, registering a CAGR of 23.9% from 2025 to 2030. This rapid expansion is driven by rising demand for high-precision mapping, surveying, and environmental monitoring across automotive, construction, agriculture, and infrastructure sectors. Advancements in LiDAR technology-particularly improved accuracy, miniaturization, and reduced costs-are widening adoption in both legacy…
U.S. Dental Implant Market to Reach USD 2.9 Billion by 2030, Powered by Technolo …
The U.S. dental implant market, valued at USD 1.5 billion in 2023, is projected by DataM Intelligence to grow at a CAGR of 10.4% from 2024 to 2030. This growth is driven by increasing patient awareness, higher disposable incomes, and a strong preference for aesthetic dentistry. Dental implants are becoming the preferred option over bridges and dentures due to their durability, biocompatibility, and natural appearance.
Major factors behind market expansion include…
U.S. Digital Therapeutics Market to Reach USD 20.98 Billion by 2034, Driven by A …
The U.S. digital therapeutics market, valued at USD 3.02 billion in 2024, is projected to expand dramatically to USD 20.98 billion by 2034, growing at a CAGR of 21.38% according to DataM Intelligence. Fueled by artificial intelligence (AI), data-driven healthcare solutions, and the demand for accessible, evidence-based interventions, digital therapeutics (DTx) are redefining patient care across chronic diseases such as diabetes, obesity, mental health, and cardiovascular disorders. These software-driven therapies…
US Hydrogen Electrolyzer Market to Surge to USD 1.2 Billion by 2035, Driven by F …
The US hydrogen electrolyzer market, valued at USD 142.8 million in 2025, is forecast to reach USD 1,207.9 million by 2035, expanding at a remarkable CAGR of 23.8% according to DataM Intelligence. Federal decarbonization initiatives, rapid deployment of renewable energy projects, and state-led hydrogen hubs are accelerating the commercial rollout of electrolyzers, a critical technology for producing clean hydrogen via water electrolysis. The sector is central to the United States'…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
